[Translation] An open-label, dose-escalating, international, multicenter Phase I clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of IMD101 injection in patients with advanced malignant solid tumors
评价IMD101注射液在标准治疗失败的晚期恶性实体瘤患者中的安全性和耐受性,并探索IMD101注射液的最大耐受剂量(MTD),确定 II 期临床试验推荐剂量(RP2D)
[Translation] To evaluate the safety and tolerability of IMD101 injection in patients with advanced malignant solid tumors who have failed standard treatment, explore the maximum tolerated dose (MTD) of IMD101 injection, and determine the recommended dose (RP2D) for Phase II clinical trials.